Silence Therapeutics plc (SLN) Ownership
SLN ownership summary
as of October 18, 2026- Institutions
- 49.3% of shares outstanding
- Insiders
- 7.97% of shares outstanding
- Shares outstanding
- 62.2M
- Float
- 37.9M shares available to trade
- Short interest
- 5.02% 2.5M shares short
- Days to cover
- 3.00 short interest up 16.5% vs prior month
- Institutions 49.32%
- Insiders 7.97%
- Other investors 42.72%
SLN top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Siren, L.L.C. | 5.33% | 3.3M | $28.7M | +400,000 (+13.7%) | June 30, 2026 |
| 2 | TCG Crossover Management, LLC | 4.88% | 3.0M | $26.3M | — | June 30, 2026 |
| 3 | Nantahala Capital Management, LLC | 4.33% | 2.7M | $23.4M | +546,731 (+25.5%) | June 30, 2026 |
| 4 | Redmile Group, LLC | 3.48% | 2.2M | $18.8M | — | June 30, 2026 |
| 5 | Citadel Advisors Llc | 2.14% | 1.3M | $11.5M | +94,818 (+7.7%) | June 30, 2026 |
| 6 | Nextech Invest, Ltd. | 1.53% | 952K | $8.3M | — | June 30, 2026 |
| 7 | Millennium Management LLC | 1.46% | 909K | $7.9M | −164,912 (−15.4%) | June 30, 2026 |
| 8 | Ikarian Capital, LLC | 1.34% | 831K | $7.2M | −35,000 (−4.0%) | June 30, 2026 |
| 9 | Polygon Management Ltd | 1.23% | 764K | $6.6M | +134,095 (+21.3%) | June 30, 2026 |
| 10 | Soleus Capital Management, L.P. | 1.01% | 630K | $5.5M | +630,000 (0.0%) | June 30, 2026 |
| 11 | Balyasny Asset Management LLC | 0.98% | 611K | $5.3M | +610,980 (0.0%) | June 30, 2026 |
| 12 | 5AM Venture Management, LLC | 0.77% | 476K | $4.1M | — | June 30, 2026 |
| 13 | Great Point Partners LLC | 0.72% | 450K | $3.9M | −570,489 (−55.9%) | June 30, 2026 |
| 14 | Morgan Stanley - Brokerage Accounts | 0.65% | 403K | $3.5M | +337,686 (+515.7%) | June 30, 2026 |
| 15 | Ameriprise Financial Inc | 0.60% | 370K | $3.2M | +370,052 (0.0%) | June 30, 2026 |
| 16 | Jane Street Group LLC | 0.59% | 369K | $3.2M | +268,224 (+265.8%) | June 30, 2026 |
| 17 | ADAR1 Capital Management LLC | 0.54% | 338K | $2.9M | +166,216 (+96.5%) | June 30, 2026 |
| 18 | SummitTX Capital, L.P | 0.53% | 327K | $2.8M | +326,648 (0.0%) | June 30, 2026 |
| 19 | Schonfeld Strategic Advisors LLC | 0.43% | 269K | $2.3M | +269,348 (0.0%) | June 30, 2026 |
| 20 | UBS Group AG | 0.39% | 243K | $2.1M | −3,785 (−1.5%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 12 holders added 4.2M shares and 4 cut 774K.
SLN top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Select Biotechnology | 3.29% | 2.0M | $17.7M | +1.9M (+1,866.0%) | August 31, 2026 |
| 2 | MEDICAL BioHealth EUR Acc | 1.35% | 837K | $7.3M | +293,755 (+54.0%) | August 31, 2026 |
| 3 | International Biotechnology Ord | 0.97% | 604K | $5.2M | −126,026 (−17.3%) | June 30, 2026 |
| 4 | Fidelity Advisor Biotechnology I | 0.86% | 532K | $4.6M | +49,700 (+10.3%) | August 31, 2026 |
| 5 | Fidelity Select Health Care | 0.80% | 500K | $4.3M | +500,000 (0.0%) | August 31, 2026 |
| 6 | apo Medical Opportunities R | 0.63% | 391K | $3.4M | +145,900 (+59.5%) | August 31, 2026 |
| 7 | iShares Biotechnology ETF | 0.47% | 290K | $2.5M | −2,200 (−0.8%) | September 30, 2026 |
| 8 | Fidelity Advisor Health Care I | 0.37% | 228K | $2.0M | +228,000 (0.0%) | August 31, 2026 |
| 9 | RIM Global Bioscience EUR | 0.19% | 116K | $1.0M | +15,000 (+14.8%) | June 30, 2026 |
| 10 | Alger Small Cap Growth A | 0.17% | 106K | $917,294 | +105,679 (0.0%) | July 31, 2026 |
| 11 | abrdn World Healthcare | 0.17% | 105K | $911,400 | +105,000 (0.0%) | August 31, 2026 |
| 12 | Fidelity VIP Health Care Initial | 0.14% | 85K | $737,800 | +85,000 (0.0%) | August 31, 2026 |
| 13 | Alger Small Cap Growth I-2 | 0.13% | 83K | $724,016 | +83,412 (0.0%) | July 31, 2026 |
| 14 | Galileo - Biotech Innovation Fund S USD | 0.09% | 59K | $509,039 | — | March 31, 2026 |
| 15 | Alger Small Cap Growth Institutional I | 0.07% | 41K | $358,415 | +41,292 (0.0%) | July 31, 2026 |
| 16 | iShares Nasdaq US Biotech ETF USD Acc | 0.06% | 40K | $348,615 | +340 (+0.9%) | September 30, 2026 |
| 17 | WEALTHGATE Biotech Fund Inst | 0.06% | 38K | $332,704 | +38,330 (0.0%) | June 30, 2026 |
| 18 | State Street® SPDR® S&P® Intl Sm Cp ETF | 0.04% | 22K | $189,224 | — | September 30, 2026 |
| 19 | Fidelity Nasdaq Composite Index | 0.03% | 16K | $138,698 | −13,559 (−45.9%) | August 31, 2026 |
| 20 | ActivePassive International Equity ETF | 0.02% | 9,520 | $82,634 | — | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
SLN shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns SLN
Institutional investors own 49.3% of Silence Therapeutics's shares and insiders 7.97%. The largest holder is Siren, L.L.C. with 5.33% of the shares (3.3M), as of June 30, 2026. Among the top 20 institutions, 12 added shares and 4 reduced their stake in the latest filings. Short interest is 5.02% of the float, or 3.00 days of average trading volume. The share count fell 9.3% since 2014.
Related: SLN analyst forecast, SLN key metrics. See the SLN stock overview for the latest quote and news.
SLN ownership FAQ
Who owns the most Silence Therapeutics stock?
The largest shareholders of Silence Therapeutics are Siren, L.L.C. (5.33%), TCG Crossover Management, LLC (4.88%), Nantahala Capital Management, LLC (4.33%), Redmile Group, LLC (3.48%), Citadel Advisors Llc (2.14%).
What percentage of Silence Therapeutics is owned by institutions?
Institutions hold 49.3% of Silence Therapeutics's shares outstanding; insiders hold 7.97%.
Which funds own Silence Therapeutics?
The largest fund holders of Silence Therapeutics are Fidelity Select Biotechnology (3.29%), MEDICAL BioHealth EUR Acc (1.35%), International Biotechnology Ord (0.97%), Fidelity Advisor Biotechnology I (0.86%), Fidelity Select Health Care (0.80%).
What is Silence Therapeutics's short interest?
2.5M shares of Silence Therapeutics were sold short, 5.02% of the float; at the average daily volume it would take 3.00 days to cover.
How many shares of Silence Therapeutics are outstanding?
Silence Therapeutics has 62.2M shares outstanding, of which 37.9M are in the public float.